NCT07365059

Safety and Efficacy of GPRC5D CAR-T Cell Therapy in Relapsed/Refractory Plasma Cell Disorders

Clinical Study on Safety and Efficacy of GPRC5D CAR-T Cell Therapy in Relapsed/Refractory Plasma Cell Disorders

• Status: Not Yet Recruiting
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 18 (estimated)
• Sponsor: Qi deng · Academic / Other
• Sex: All
• Age: 14 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This study is an open-label, single-arm, dose-escalation and expansion, prospective clinical trial. It enrolls patients with relapsed/refractory plasma cell disorders, administers GPRC5D CAR-T cell therapy, follows up to observe adverse reactions after medication, collects relevant data on treatment efficacy, evaluates the safety and efficacy of CAR-T cells, and simultaneously investigates the cellular kinetic characteristics of CAR-T cells.

Conditions

• Plasma Cell Dyscrasias

Interventions

Type	Name	Description
BIOLOGICAL	GPRC5D CAR-T cell intravenous infusion	GPRC5D CAR-T cell intravenous infusion

Timeline

• Start date: 2026-01-25
• Primary completion: 2029-01-01
• Completion: 2029-03-01
• First posted: 2026-01-26
• Last updated: 2026-01-26